Cardiovascular, Autonomic, and Vascular Research

1 MCAM Multi-Site Autonomic Dysfunction Study

  • Principal Investigator:: Elizabeth Unger and collaborators

  • Institution:: CDC / multi-site (USA)

  • Contact/URL:: https://doi.org/10.3390/jcm14176269

  • Funder:: CDC

  • Status:: Published 2025

  • Phase:: Observational (multi-site clinical assessment)

  • Cohort:: ME/CFS patients from the MCAM (Multi-Site Clinical Assessment of ME/CFS) programme

  • Mechanism/Focus:: Characterised autonomic dysfunction using COMPASS-31 scores and the NASA lean test. Demonstrated high prevalence of autonomic symptoms across ME/CFS cohorts regardless of recruitment site.

  • Primary Outcomes:: Autonomic dysfunction symptoms are pervasive in ME/CFS; COMPASS-31 scores significantly elevated versus controls

  • Estimated Completion:: Published

  • Publication Medium:: Journal of Clinical Medicine

  • Document Relevance:: Ch. 10 (cardiovascular), Ch. 8 (neurological dysfunction—autonomic)

The MCAM study’s multi-site design strengthens generalisability: autonomic dysfunction is not an artefact of specialist referral patterns but a consistent feature across diverse clinical settings (Issa et al. 2025). The NASA lean test used here is simpler than head-up tilt, making it a practical screening tool for primary care.

2 Small Fibre Neuropathy in ME/CFS and Post-COVID

  • Principal Investigator:: Naia Azcue and collaborators

  • Institution:: Multi-centre (Spain)

  • Contact/URL:: https://doi.org/10.1111/ene.70016

  • Funder:: Institutional

  • Status:: Published 2025

  • Phase:: Observational (case-control)

  • Cohort:: ME/CFS patients, post-COVID patients, and healthy controls

  • Mechanism/Focus:: Assessed small fibre neuropathy using electrochemical skin conductance, nerve reaction times to temperature stimuli, and corneal confocal microscopy. Both ME/CFS and post-COVID patients showed significantly higher autonomic and neuropathic symptom burden than controls.

  • Primary Outcomes:: SFN features present in both ME/CFS and post-COVID; corneal nerve fibre density reduced

  • Estimated Completion:: Published

  • Publication Medium:: European Journal of Neurology

  • Document Relevance:: Ch. 8 (neurological dysfunction), Ch. 10 (cardiovascular—perfusion), Ch. 14 Speculative Cross-Disease Connections

Small fibre neuropathy provides an objective, quantifiable marker for a symptom—neuropathic pain and dysautonomia—that is otherwise self-reported (Azcue et al. 2025). The corneal confocal microscopy approach is non-invasive and could serve as a bedside diagnostic. The shared SFN phenotype between ME/CFS and post-COVID strengthens the case for common neurovascular pathology.

3 Microvascular Remodelling and Endothelial Dysfunction

  • Principal Investigator:: Multiple groups

  • Institution:: Multi-centre (Europe)

  • Contact/URL:: https://doi.org/10.64898/2026.01.22.26344661

  • Funder:: Institutional

  • Status:: Preprint January 2026

  • Phase:: Observational (case-control)

  • Cohort:: Post-COVID and ME/CFS patients versus healthy controls

  • Mechanism/Focus:: Used retinal vessel analysis as a non-invasive measure of systemic microvascular health. Identified reduced venular flicker-induced dilation in patients, indicating ongoing endothelial dysfunction even in clinically stable individuals.

  • Primary Outcomes:: Endothelial dysfunction detectable via retinal imaging; reduced venular reactivity in ME/CFS and post-COVID

  • Estimated Completion:: Preprint published; peer review pending

  • Publication Medium:: medRxiv

  • Document Relevance:: Ch. 10 (cardiovascular), Ch. 13 (integrative models)

Retinal vessel analysis offers a window into systemic microvascular health without invasive procedures (2026). The persistent endothelial dysfunction in clinically stable patients suggests ongoing vascular injury that may underlie fatigue and cognitive symptoms even when patients report partial recovery. This complements the microclot findings (Nunes et al. 2022) and the coagulation proteomics data (2024).

4 POTS Autonomic Profiling Across Aetiologies

  • Principal Investigator:: Multiple groups

  • Institution:: Multi-centre

  • Status:: Published 2025

  • Phase:: Observational (comparative)

  • Cohort:: POTS patients from syncope, CFS, and post-COVID-19 populations

  • Mechanism/Focus:: Identified distinct autonomic profiles: syncope-related POTS showed baroreceptor dysfunction and sympathetic predominance, whereas CFS-related POTS was characterised by parasympathetic impairment and impaired short-term baroreflex regulation.

  • Primary Outcomes:: CFS-related POTS has a distinct autonomic signature from syncope-related and post-COVID POTS

  • Estimated Completion:: Published

  • Document Relevance:: Ch. 10 (cardiovascular), Ch. 8 (neurological dysfunction—autonomic)

The distinction between CFS-related and syncope-related POTS autonomic profiles has therapeutic implications: parasympathetic impairment in CFS-related POTS suggests vagal tone-targeting interventions (e.g., tVNS, Section Clinical Trials (Interventional)) may be more appropriate than the beta-blockade used for hyperadrenergic POTS (2025).

References

2024. “Data-Independent LC-MS/MS Analysis of ME/CFS Plasma Reveals a Dysregulated Coagulation System, Endothelial Dysfunction, Downregulation of Complement Machinery.” Journal of Translational Medicine.
———. 2025. “Comprehensive Assessment of Autonomic Nervous System Profiles in Postural Orthostatic Tachycardia Syndrome Among Syncope, Chronic Fatigue, and Post-COVID-19 Patients.” PLoS One.
———. 2026. “Microvascular Remodeling and Endothelial Dysfunction Across Post-COVID-19 and ME/CFS.” medRxiv. https://doi.org/10.64898/2026.01.22.26344661.
Azcue, Néstor et al. 2025. “Small Fiber Neuropathy in the Post-COVID Condition and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Significance and Diagnostic Challenges.” European Journal of Neurology 32 (2): e70016. https://doi.org/10.1111/ene.70016.
Issa, Anindita, Jin-Mann S Lin, Yang Chen, Jacob Attell, Dana Brimmer, Jeanne Bertolli, Benjamin H Natelson, et al. 2025. “Autonomic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Findings from the Multi-Site Clinical Assessment of ME/CFS (MCAM) Study in the USA.” Journal of Clinical Medicine 14 (17): 6269. https://doi.org/10.3390/jcm14176269.
Nunes, Jean M., Arneaux Kruger, Amy Proal, Douglas B. Kell, and Etheresia Pretorius. 2022. “The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Pharmaceuticals 15 (8): 931. https://doi.org/10.3390/ph15080931.